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Acute respiratory tract infections (RTIs) of viral origin place a substantial burden on health 
care resources and society. Randomized controlled trials have shown positive effects of 
probiotics on clinical outcomes in these commonly occurring RTIs. Two meta-analyses 
published by the York Health Economics Consortium (YHEC) and Cochrane reported 
the efficacy of probiotics in reducing incidence and duration of RTIs, number of antibiotic 
courses, and days absent from work. The aim of this study was to assess the potential 
health-economic impact of probiotics on RTI-associated events and expenses in the 
US primary care setting. A state-transition microsimulation model reproduced a study 
population representative of the US national demographics for age and gender (1/1,000 
sample). RTI incidence was based on the influenza-like illness outpatient consultation 
rate reported by the Centers for Disease Control and Prevention (CDC) FluView. Data on 
vaccination, on factors that negatively impact RTI outcomes, on resource utilization, and 
on productivity loss were obtained from US national databases. Analyses were performed 
for both meta-analyses independently. Outcomes included cost savings for the health care 
payer, related to a reduced number of RTI episodes, less outpatient consultations, and 
decreased medical prescriptions as well as cost savings from a broader societal perspective 
related to productivity loss. The analysis showed that generalized probiotic intake in the US 
population for 2017–2018 would have allowed cost savings for the health care payer of 4.6 
million USD based on the YHEC scenario and 373 million USD for the Cochrane scenario, by 
averting 19 million and 54.5 million RTI sick days, respectively, compared to no probiotics. 
Antibiotic prescriptions decreased with 1.39–2.16 million courses, whereas absence from 
work decreased by 3.58–4.2 million days when applying the YHEC and Cochrane data, 
respectively. When productivity loss is included, total savings for society represented 784 
million or 1.4 billion USD for the YHEC and Cochrane scenarios, respectively. Subgroup 
analyses demonstrated an incremental benefit of probiotics in at-risk groups, which might 
be of relevance for targeted interventions. Sensitivity analyses confirmed the robustness 
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of the model outcomes. Our analysis demonstrated a positive impact of probiotics on the 
health care and economic burden of flu-like RTIs. Improved disease outcomes translated 
into considerable cost savings for both the payer and society.
Keywords: probiotics, health economics, respiratory tract infection, influenza, cost savings
INTRODUCTION
Acute respiratory tract infection (RTI) is a frequent illness, 
generally of viral origin. Clinical conditions range from mild 
cold symptoms to influenza, the most serious form of common 
acute RTI. In most health care settings, diagnostic tests that 
would differentiate between influenza and other forms of viral 
RTIs are not routinely performed. Although most acute RTI 
episodes resolve spontaneously (Dasaraju and Liu, 1996), RTIs 
result in a high number of outpatient consultations and pose 
a heavy burden on society and health care systems. Strategies 
to reduce the incidence and effects of common acute RTIs 
attract major public health interest, given the large number of 
individuals affected each year as well as the impact on patient 
health outcomes and on medical and personal costs. In order 
to facilitate disease monitoring, this overlapping group of acute 
viral respiratory infections is generally referred to as influenza-
like illness (ILI) (Fowlkes et al., 2014). Recently, the WHO 
defined ILI as “an acute respiratory illness with a measured 
temperature of >38°C and cough, with [symptom] onset within 
the past 10 days” (Fitzner et al., 2018). In the USA, information 
on outpatient visits to health care providers for ILI is collected 
through the US Outpatient Influenza-like Illness Surveillance 
Network (CDC ILInet, 2018). For this system, ILI is defined as 
having a fever (>100°F or >37.8°C) and cough and/or sore throat 
(in the absence of a known cause).
Probiotics are live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host (Hill 
et al., 2014). Interest in the potential impact of probiotics on 
health outcomes has been increasing in recent years. This impact 
has been investigated in several therapeutic areas, including 
RTIs. According to a recent survey among health care providers 
who routinely prescribe medication, 61% had recommended 
probiotic food or supplements to their patients (Draper et al., 
2017). Several clinical studies have evaluated the effectiveness 
of probiotics when administered to healthy subjects in reducing 
the incidence and duration of infectious respiratory conditions 
(de Vrese et al., 2005; Leyer et al., 2009; Berggren et al., 2011). 
Two large meta-analyses have investigated the preventative effect 
of taking probiotics versus placebo. The York Health Economics 
Consortium (YHEC) performed a systematic review and meta-
analysis on the duration of illness in healthy children and adults 
who developed acute respiratory infectious conditions (King 
et al., 2014); results showed that probiotics significantly reduced 
RTI episode duration. The Cochrane Collaboration assessed 
the effectiveness of probiotics, compared with placebo, in the 
prevention of acute upper RTIs in healthy people of all ages and 
reported that probiotics reduced RTI incidence and antibiotic 
prescription rate (Hao et al., 2015).
OBJECTIVES
Based on the above-mentioned meta-analyses reporting the 
positive outcomes of probiotics in RTI, we hypothesized that 
generalized use of probiotics would meaningfully reduce RTI 
duration and/or frequency and thus the use of health care resources 
and related expenses for RTI in the USA. The objective of this 
study was to quantify the effect of probiotics on RTI-related health 
and cost outcomes in the US primary care setting. The analysis also 
explored the effect of probiotic intake on productivity loss.
METHODS
Model Description
Our economic analysis compared generalized probiotic 
intake versus no probiotic intake. We used a state-transition 
microsimulation model, which enabled us to track the disease 
pathway of each subject, accumulating costs and events dependent 
on individual baseline and/or time-varying characteristics. Two 
previously published economic evaluations of probiotics in RTIs 
inspired the model structure (Lenoir-Wijnkoop et al., 2015; Lenoir-
Wijnkoop et al., 2016). The study cohort was a representative 
sample of the US population in terms of demographics and known 
RTI-related risk factors. Model convergence was tested in order to 
ensure that the number of individuals in the analysis was sufficient 
to obtain robust results. The model comprised two health states, “at 
risk” and “ongoing RTI” (Figure 1).
All individuals in the cohort were evaluated under each of the 
two probiotic intake regimens, generalized probiotic use versus no 
probiotic use. For the analysis of each regimen, each subject started 
FIGURE 1 | Model structure.
Probiotic Intake and Acute ARTI Cost-SavingsLenoir-Wijnkoop et al.
3 August 2019 | Volume 10 | Article 980Frontiers in Pharmacology | www.frontiersin.org
in the “at-risk” state and could move to “ongoing RTI” according 
to predefined transition probabilities, calculated based on US 
epidemiology data. The cycle length was 1 day, and the time horizon 
was 1 year, reflecting the 2017–2018 influenza season of FluView 
data from the Centers for Disease Control and Prevention (CDC).
Model Inputs and Data Sources
Probiotic Effect
The clinical effects of probiotics were obtained from the meta-
analyses published by the YHEC (King et al., 2014) and Cochrane 
(Hao et al., 2015). These were used to conduct two independent 
scenario analyses comparing generalized probiotic use versus 
non-use, each based on different assumptions: YHEC showed a 
significantly shorter duration of −0.77 days [−1.50 to −0.04] on an 
average duration of 7.4 days per episode of RTI, among otherwise 
healthy children and adults taking probiotics compared to those 
taking placebo. The Cochrane study reported that probiotics 
significantly reduced RTI duration by 1.89 days [1.75 to 2.03] per 
episode of an average duration of 8.82 days and RTI incidence by 
30% (RR = 0.70 [0.50 to 0.84]) (Table 1). The authors also found 
a significant reduction of the antibiotic prescription rate of 35% 
TABLE 1 | Summary of model inputs—epidemiological and resource utilization parameters.
Model parameters Reference
Influenza vaccination coverage CDC Fluvaxview, 2018
Steps to ILI incidence estimation
All cause consultations, all ages NAMCS
Total ILI consultations, all ages CDC FluView, 2018
Clinical effect of probiotics
YHEC On RTI incidence: NA/On RTI duration: –0.77 days vs placebo/On antibiotic use: NA/
On work absenteeism: –0.17 SMD
King et al., 2014
Cochrane On RTI incidence: RR = 0.70* vs placebo/On RTI duration: –1.89 days vs placebo/On 
antibiotic use: RR = 0.65 vs placebo/On work absenteeism: NA
Hao et al., 2015
Risk factors
Smoking
Active smokers CDC MMWR, 2018a, CDC 
MMWR, 2018b
Passive smokers National Cancer Institute, 2017
Shared indoor environment
School enrollment United States Census Bureau, 
2018b
Employment status Bureau of Labor Statistics, 
2018
Living in a nursing home Henry J Kaiser Family 
Foundation, 2019b
Impact of risk factors on RTI
Smoking
Active smokers On RTI incidence: NA/On RTI duration: +16.8% vs no smokers Benseñor et al., 2001
Passive smokers On RTI incidence: RR = 1.15/On RTI duration: +4.5% vs no smokers Benseñor et al., 2001
Shared indoor environment
Day care (including school) vs home care On RTI incidence: RR = 1.22/On RTI incidence: NA Louhiala et al., 1995
Shared office vs alone On RTI incidence: RR = 1.07/On RTI incidence: NA Jaakkola and Heinonen, 1995
Cost parameters
Direct cost parameters % using the 
resource
Unit cost (by payer) (USD) Copayment (USD)
PCP cost# 100% 74.16** 25** Physician Fee Schedule
Antibiotics (amoxicillin)§ 29% 6.49 0 Medi-Span Price Rx 2018
Non-antibiotic medication 56.62% 26.59 11 Karve et al., 2013
Indirect cost parameters % missed days Number of missed days, 
mean (SD)
Cost per day lost 
(employer) (USD)†
Employee with ILI 42% 1.7 (5.1) 217.92 Palmer et al., 2010, Bureau of 
Labor Statistics, 2018
Sick children with ILI 18% 0.5 (1.5) 217.92 Palmer et al., 2010, Bureau of 
Labor Statistics, 2018
SMD, standardized mean difference; NA, not applicable; CDC, Centers for Disease Control and Prevention; ILI, influenza-like illness; NAMCS, National Ambulatory Medical Care 
Survey; YHEC, York Health Economics Consortium; RTI, respiratory tract infection; RR, risk ratio; MMWR, Morbidity and Mortality Weekly Report; PCP, primary care physician.
*Transformed from OR to RR using exact numbers and sample size.
**Reimbursed unit price of current procedural terminology code 99213.
#Published by the Centers for Medicare & Medicaid Services.
§Commonly used and recommended for by the CDC.
†Cost per absent day is based on daily wage from (Bureau of Labor Statistics, 2018).
Probiotic Intake and Acute ARTI Cost-SavingsLenoir-Wijnkoop et al.
4 August 2019 | Volume 10 | Article 980Frontiers in Pharmacology | www.frontiersin.org
(RR = 0.65 [0.45 to 0.94]), which was applied to both scenarios. 
Additionally, the YHEC meta-analysis studied the impact of 
probiotics on work absenteeism. The reported standardized mean 
difference (SMD) in the number of days absent from work was 
used to estimate the impact of probiotics on productivity loss. The 
Cochrane meta-analysis focused on unvaccinated individuals; 
therefore, no impact of probiotics sourced from the Cochrane meta-
analysis was applied in vaccinated patients.
Demographic Structure of the Study Population
The demographic data by age and gender were obtained from the 
United States Census Bureau (2018a).
Respiratory Tract Infection Incidence and 
Vaccination Status
The daily RTI incidence probabilities were estimated based on 
the ILI outpatient consultation rate as reported by CDC FluView 
(2018). The vaccination status of American citizens was taken 
into account in the base case to allow exclusion of a probiotic 
effect in vaccinated patients, as the Cochrane scenario excluded 
vaccinated subjects. That is, for a vaccinated patient, we specified 
that RTI incidence and duration were identical between the 
probiotic and no-probiotic scenarios, effectively excluding 
probiotic effects for vaccinated patients. The prevalence of 
influenza vaccination in the USA was obtained from the CDC 
Fluvaxview (2018). The lower probability of getting ILI for 
vaccinated subjects was estimated based on the vaccination 
effect reported by two meta-analyses, Jefferson et al., (2008) and 
Demicheli et al. (2018) for children and adults, respectively.
Risk Factors
Several risk factors other than age are known to have an impact 
on RTI, such as smoking or a daily shared indoor environment. 
To guarantee stable and robust results, these risk factors were 
not part of the base case but were included in subgroup analyses 
that assessed the variability of the results across different 
subpopulations and identified subpopulations likely to benefit 
more from the use of probiotics.
Benseñor et al. (2001) carried out a randomized controlled 
trial (RCT) among 39,876 female participants to assess active 
and passive smoking in relation to frequency of colds. The study 
showed no significant impact of active smoking on upper RTI 
incidence, while it significantly increased the risk of having 
a longer duration (RR > 7 days) of 1.62 [1.40 to 1.87] for light 
smokers and 2.63 [2.02 to 3.44] for heavy smokers. In passive 
smokers, a higher RTI incidence [1.15 (1.05 to 1.26)] and a 
longer RTI duration per episode [4.5 (0.1 to 8.9)] were observed 
in comparison to non-smokers.
The CDC Morbidity and Mortality Weekly Report (MMWR) 
published the prevalence of active smoking among adults (CDC 
MMWR, 2018a) as well as among middle and high school students 
(CDC MMWR, 2018b). The prevalence of passive smoking was 
obtained from the National Cancer Institute (2017).
Daily shared indoor environments (i.e. children studying in 
school and adults working in a shared office) have been shown to 
increase the risk of acquiring an RTI, with an associated impact 
on RTI incidence (Dasaraju and Liu, 1996). Children in day care 
centers, aged 1–7 years, appeared to have a significantly higher 
risk of getting a respiratory infection than children staying at 
home [1.22 (1.13 to 1.31)] (Louhiala et al., 1995). In the model, 
this effect was also applied for children aged 8–15  years. The 
results of a study on adults working in a shared office environment 
showed a higher risk of having more than two cold episodes 
during a 12-month period [1.64 (1.08 to 2.50)] (Jaakkola and 
Heinonen, 1995). Prevalence of shared indoor environments 
was based on school enrollment (United States Census Bureau, 
2017), employment status (Bureau of Labor Statistics, 2018), and 
proportion of people living in a nursing home (Henry J Kaiser 
Family Foundation, 2019b).
Respiratory Tract Infection-Related Costs
Resource utilization consisted of estimated consultation fees 
for a primary care physician (PCP), cost of antibiotics and 
other prescribed medication resource use, and copayment 
(Henry J Kaiser Family Foundation, 2017a). Inpatient costs 
were not considered. Cost for consulting a PCP was taken from 
the Physician Fee Schedule (Centers for Medicare & Medicaid 
Services, 2018) and based on the assumption of a single PCP 
consultation per RTI episode to align with the estimates of the 
RTI incidence derived from the number of ILI outpatient visits, 
collected through the US Outpatient Influenza-like Illness 
Surveillance Network (CDC ILInet, 2018). The cost of antibiotics 
was based on a recent study that reported an antibiotic prescription 
during influenza seasons of 29% (Havers et al., 2018). Due to 
the lack of data availability, prescribed medications other than 
antibiotics were included in this analysis as a single cost item, 
based on a publication that assessed health care costs associated 
with influenza (Karve et  al., 2013). The cost of over-the-counter 
medication among the general population was not included, as 
reliable information on cost estimates was insufficient.
A broader societal perspective was taken by combining 
the cost covered by insurance/copayment and ILI-related 
productivity losses (Palmer et al., 2010). An overview of all data 
inputs and sources is presented in Table 1.
Statistical Analyses
The model was used to quantify the impact of generalized probiotic 
use versus no probiotic use on each of the following outcomes: 
number of ILI events, number of ILI days, number of antibiotic 
prescriptions, number of days missed from work, PCP visit costs, 
medication costs, and productivity loss. Subgroup analyses were 
conducted on age, vaccination status, smoking status (active and 
passive), and living or working in a shared indoor environment. 
Two additional scenario analyses were conducted: (1) comparing 
a population with generalized probiotic intake versus a population 
with current probiotic intake in the USA and (2) considering an 
alternative data source for productivity loss in ILI patients.
Uncertainty around model results due to model assumptions 
was further explored in a one-way sensitivity analysis, which 
considered two key parameters: avoided RTI days and saved 
total societal cost with probiotic use versus no probiotic use 
(Table 2). All statistical analyses were performed and produced 
in Microsoft Excel (2016), and the model was developed with the 
utilization of Visual Basic for Applications (VBA) in Excel.
Probiotic Intake and Acute ARTI Cost-SavingsLenoir-Wijnkoop et al.
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Model Validity
A cohort of 329,256 individuals was generated based on the chosen 
sample rate. The model demonstrated a high precision in simulating 
the US population structure by age and gender (Figure 2). High 
accuracy was also achieved in simulating risk factor prevalence as 
well as ILI event incidence with <0.2% difference in total number 
of RTI events when compared to the FluView data.
To ensure that the model provides robust results with a chosen 
sample size, convergence testing was conducted and confirmed the 
stability of estimates for both the YHEC and the Cochrane scenarios.
RESULTS
In the YHEC scenario, the base case analysis showed that 
the shorter duration of disease associated with probiotic 
intake engendered 19,012 fewer acute RTI days compared to 
no probiotics, while 1,393 antibiotic courses (−19.4%) were 
avoided in the evaluated study cohort (Table 3). As the YHEC 
meta-analysis did not investigate the effect of probiotics on RTI 
incidence, the difference in the number of RTI episodes and 
related physician consultations was not part of the base case 
analysis. When these outcomes are projected to the actual US 
population, this translates to potential cost savings associated 
with probiotic use of 4.6 million USD for the health care payer. 
When productivity loss related to absence from work is included, 
probiotic intake has the potential for additional total cost savings 
of 784 million USD for the USA.
In the Cochrane scenario, the base case analysis of the effect 
of probiotics on both a reduced RTI incidence and a shorter 
disease duration demonstrated a decrease of 4,103 RTI episodes, 
a reduction of 54,491 RTI days, and 2,166 antibiotics courses 
averted in the probiotic arm compared to the arm without 
probiotics (Table 4). Projection of the base case outcomes to the 
US population showed that probiotic use would result in cost 
savings of 373 million USD for the health care payer. For this 
TABLE 2 | Sensitivity analyses: lower and upper bounds of variation for model parameters.
Parameter Value Source
Base case Lower Upper
YHEC scenario (probiotic effects)
Change duration per RTI episode 0.77 0.04 1.5 95% CI, King et al., 2014
Reduced antibiotic prescription (RR)* 0.65 0.45 0.94 95% CI, Hao et al., 2015
Change in loss of productivity, adults 0.87 0.153 1.581 95% CI, King et al., 2014 
+ assumptionChange in loss of productivity, children‡ 0.26 0.045 0.465
Cochrane scenario (probiotic effects)
Change in duration per RTI* episode 1.89 1.75 2.03 95% CI, Hao et al., 2015
Reduced incidence of RTI* (RR) 0.70 0.5 0.84
Reduced antibiotic prescription* (RR) 0.65 0.45 0.94
Change in loss of productivity, adults 0.87 0.153 1.581 95% CI, King et al., 2014 
+ assumptionChange in loss of productivity, children‡ 0.26 0.045 0.465
Both scenarios
Probability of non-antibiotic medication 56.62% 50.00% 60.00% Assumption based on expert 
opinion
Antibiotic cost, 0–14 years 2.95 1.48 4.43 ±50% of base case value
Antibiotic cost, 15+ years 3.54 1.77 5.31
PCP cost 99.16 69.64 124.44 Codes 99212 and 99214, 
Physician Fee Schedule
Upper and lower limits represent 95% confidence interval as reported by the indicated source. PCP, primary care physician; RR, risk ratio; RTI, respiratory tract infection; YHEC, York 
Health Economics Consortium; PCP, primary care physician.
*Applied in non-vaccinated individuals only.
‡Productivity loss caused by sick child.
FIGURE 2 | Population structure by age and gender in the model cohort 
versus USA population.
TABLE 3 | York Health Economics Consortium (YHEC) scenario: impact of 
probiotics on RTI-related events versus no probiotics (sample size 1/1,000).
Event outcome Probiotics No 
probiotics
Difference Difference 
in %
RTI days 163,701 182,713 −19,012 −10.41%
No. of antibiotic 
courses
5,804 7,197 −1,393 −19.36%
No. of missed 
work days
3,397 6,973 −3,576 −51.29%
RTI, respiratory tract infection.
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scenario, when generalized probiotic use versus no probiotic use 
are compared, the total decrease in RTI-associated expenses due 
to medical resource utilization and productivity loss combined 
equaled 1.4 billion USD.
Subgroup analyses of risk factors showed that an incremental 
benefit of probiotics was observed in children aged ≤15 years, 
in individuals sharing a daily indoor environment, and in 
passive smokers. The positive impact of probiotics was highest 
in the pediatric population that constituted 19.8% of the 
cohort population, but in which probiotic use contributed to 
41.3% of avoided RTI days and 26.3% of the total cost savings. 
Results of the unvaccinated subgroup analysis showed that the 
53.7% of unvaccinated individuals in the model population 
contributed to 56% of avoided RTI days and 63.9% of saved 
total costs. The outcomes of the subgroup analyses are 
summarized in Table 5.
In the base case analysis, current probiotic intake was 
disregarded even though probiotic consumption would 
be expected to influence the reported RTI incidences and 
subsequently our study outcomes. Therefore, a scenario analysis 
was carried out based on estimated probiotic intake. According to 
the National Health Interview Survey (NHIS), 1.6% of American 
adults take probiotics and/or prebiotics as dietary supplements 
(Clarke et al., 2015). Further, it has been estimated that dietary 
supplements account for about 36% of the probiotic sales in the 
USA; the remaining 64% of the market represents thus probiotic 
foods (Vanderhoof and Young, 2008). Therefore, an overall 4.4% 
probiotic intake among the US population was used to include 
current probiotic consumption in a scenario analysis. This 
showed that outcomes were only slightly different from the base 
case, confirming the robustness of the model.
DISCUSSION
We developed a state-transition microsimulation model to 
quantify the effect of probiotics on RTI-related health and cost 
outcomes in the USA. The analysis considered the impact of 
generalized probiotic intake from a health care payer’s perspective 
in primary care, as well as in a broader societal setting by including 
productivity loss associated with flu-like RTI. The model accurately 
reproduced the US population structure, the incidence pattern, and 
the risk factor prevalence over the study period. Two meta-analyses 
reported clinical benefits of probiotics, one showing a reduction of 
disease duration and the other both a decrease of disease incidence 
and duration (Table 1). While the changes are small at an individual 
level, when applied to the US population, the health impact is 
sizable, ranging from an estimated 19,012,000 to 54,491,000 fewer 
RTI days, 1,393,000 to 2,166,000 averted antibiotic courses, and 
3,576,000 to 4,217,000 avoided missed work days, according to 
the YHEC scenario and the Cochrane scenario, respectively. The 
Cochrane scenario showed a higher overall impact on public 
health, due to the fact that it considered both a shorter RTI duration 
and a reduced RTI incidence. In terms of cost savings, the impact of 
avoided RTI events, translated to the US population, represented a 
potential total amount of approximately 1.4 billion USD, of which 
370 million USD represents savings for the health care payer.
When cross-validation is performed, the findings of this US 
analysis were consistent with the previously published French 
and Canadian assessments (Lenoir-Wijnkoop et al., 2015; Lenoir-
Wijnkoop et al., 2016). The proportion of avoided RTI days in the 
population with probiotics versus no probiotics in the models was 
similar to the results in the current analysis for both the YHEC 
and Cochrane scenarios. Differences in other outcomes were 
TABLE 5 | Subgroup analysis by risk factors (age, smoking, and living in a shared daily environment) (sample size 1/1,000).
Subgroup % of model population % of avoided RTI days % of total societal cost savings
YHEC scenario
Children (aged 0–15) 19.81% 41.30% 26.29%*
Passive smokers 26.59% 34.60% 30.03%
Individuals with shared indoor 
environments
53.19% 55.55% 71.88%
Unvaccinated individuals 53.70% 56.10% 63.87%
Cochrane scenario
Children (aged 0–15) 19.81% 34.35% 34.62%*
Active smokers 12.50% 11.93% 13.13%
Passive smokers 26.59% 34.11% 31.23%
Individuals with shared indoor 
environments
53.19% 58.25% 67.24%
RTI, respiratory tract infection; YHEC, York Health Economics Consortium.
*Excluding productivity loss.
TABLE 4 | Cochrane scenario: impact of probiotics on RTI-related events versus no probiotics (sample size 1/1,000).
Event outcome Probiotics No probiotics Difference Difference in %
RTI episodes 20,568 24,671 −4,103 −16.63%
RTI days 163,107 217,598 −54,491 −25.04%
No. of antibiotic courses 5,026 7,192 −2,166 −30.12%
No. of missed work days 2,753 6,971 −4,217 −60.50%
RTI, respiratory tract infection.
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to be expected due to country-specific characteristics, related 
to vaccination coverage, prescription patterns, cost inputs, or 
different conditions in absence from work.
Strengths and Limitations
In the present analysis, we accurately simulated the US general 
population structure, vaccination status and prevalence, and the 
ILI incidence pattern of the studied flu season. The incidence 
data represented only the proportion of PCP visits due to ILIs, 
which is known to be relatively low (Biggerstaff et al., 2014; 
Peppa et al., 2017) and likely lead to an underestimation.
One of the base case scenarios only considered the effects of 
probiotics among the unvaccinated individuals, in line with the 
results of the Cochrane meta-analysis. The results of the model 
were therefore conservative, since probiotics can potentially have 
effects on the vaccinated individuals (Yaqoob, 2014; Zimmermann 
and Curtis, 2018). Another aspect of probiotic intake not captured 
in the model concerns the role probiotics may play in the reduction 
of antibiotic use (King et al., 2018). The CDC estimates that of 
the 44% of outpatient antibiotics prescribed to treat patients with 
respiratory conditions, half are unneeded (CDC Newsroom, 
2016). Reduced antibiotic use and the associated risk of antibiotic 
resistance may have considerable public health relevance as well 
as additional cost consequences (Michaelidis et al., 2016).
A limitation of our analysis is that probiotics were considered 
as a general category and not included in our assessment at the 
strain level. Different probiotic strains may have different effects 
on RTIs, but because our evaluation was based on two specific 
meta-analyses, we effectively included all relevant probiotic strains 
evaluated in one or more of the clinical trials that were pooled via 
these meta-analyses. Further, data available for probiotic use in the 
USA are not segregated based on specific strains. Advances have 
been made in unraveling the wide array of molecular mechanisms 
by which probiotic organisms can interact with host cells and 
on understanding how this might translate into a clinical effect 
(Kleerebezem et al., 2019). Certain health benefits depend on core 
properties that are conserved among different probiotics, while 
other benefits appear to be more strain specific (Hill et al., 2014; 
Sanders et al., 2018). An expression of shared efficacy among many 
different strains may derive from common mechanisms among 
taxonomic groups that are at a higher order than a strain, such 
as species or genus. An example of such a shared mechanism is 
production of short-chain fatty acids. In the case of prevention of 
RTIs, the mechanism is not known, although it may likely involve 
probiotic interactions with the immune system. For purposes of 
this analysis, we consider it sufficient to note that studies included 
in the meta-analyses, upon which it is based, included interventions 
from a variety of different Lactobacillus and Bifidobacterium strains.
As in the previous French and Canadian analyses (Lenoir-
Wijnkoop et al., 2015, Lenoir-Wijnkoop et al., 2016), the cost of 
probiotics was not included as a factor in our model. Although 
costs of probiotic foods and dietary supplements do not weigh on 
the health care payers’ resources, their purchase may put an extra 
burden on the average household expenses. Due to an absence 
of reliable information and a great variation in products with 
a wide range of unit prices, it was not possible to evaluate how 
much this would represent. However, these additional household 
costs would probably be offset by other expenses, such as costs 
related to self-medication and purchase of over-the-counter 
drugs (Klepser, 2014) and costs related to informal care for sick 
children or the elderly (Chari et al., 2015) and associated with 
missed schooldays (Li and Leader, 2007; NCCID, 2014).
CONCLUSION
The model demonstrated a positive impact of probiotic 
consumption on health outcomes in flu-like RTI and the 
associated patient burden by reducing the number of RTI episodes, 
the number of days patients spent with RTI symptoms, and the 
need for antibiotics. Improved patient outcomes translated into 
considerable cost savings for both the payer and society. These 
results suggest that recommending daily probiotic consumption 
may be justified for particular at-risk populations, such as 
children or individuals with a shared indoor environment, for 
which this study shows a higher incremental benefit. Such action 
should be in combination with a cost-effectiveness analysis of 
implementation to further define the extent to which probiotics 
contribute to reducing both health care spending and out-of-
pocket costs for the management of flu-like infections.
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